GNH USA

Europe — EMA

Olmita (Olmesartan Medoxomil, Amlodipine)

GNH USA supplies Olmita (Olmesartan Medoxomil & Amlodipine), a combined ARB and calcium‑channel blocker for hypertension. Request a quote for global supply.

Olmesartan Medoxomil, Amlodipine

Request sourcing

1
Pack/s

What is Olmesartan Medoxomil, Amlodipine?

Olmesartan medoxomil, the active ingredient in Olmita, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and is often prescribed for adults needing blood pressure control. GNH USA supplies Olmita as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmita as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

What is Olmesartan Medoxomil, Amlodipine used for?

Olmita combines two antihypertensive agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone to lower blood pressure. - Hypertension: helps achieve target blood pressure in adults with primary hypertension. - High‑risk cardiovascular patients: contributes to risk reduction when used with lifestyle measures. - Resistant hypertension adjunct: can be added when blood pressure remains uncontrolled on monotherapy.

What are the side effects of Olmesartan Medoxomil, Amlodipine?

Olmita may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness: especially after standing. - Flushing: transient warmth and redness. - Fatigue: general tiredness. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, tongue or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Liver enzyme elevation: abnormal liver function tests. - Renal impairment: worsening kidney function. - Hyperkalemia: elevated potassium levels. - Allergic rash: severe skin reactions such as Stevens‑Johnson syndrome.

What precautions apply to Olmesartan Medoxomil, Amlodipine?

When prescribing Olmita, clinicians should consider several safety aspects. - Pregnancy contraindication: avoid use in pregnancy due to fetal risk. - Renal impairment: adjust therapy based on kidney function. - Hepatic impairment: use with caution in patients with liver disease. - Electrolyte monitoring: check potassium levels periodically. - Drug‑interaction vigilance: review concomitant medications for additive hypotensive effects. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

What does Olmesartan Medoxomil, Amlodipine interact with?

Olmita can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: avoid concurrent ACE inhibitors or other ARBs. - Potassium‑sparing diuretics or supplements: risk of hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole): may increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect. - Diuretics: may enhance hypotensive response. - Lithium: monitor lithium levels for potential toxicity.

Frequently asked questions

What is Olmita used for?+
Olmita is a fixed‑dose combination of olmesartan medoxomil and amlodipine that is prescribed to lower high blood pressure in adults. By targeting two complementary pathways that control vascular tone, it helps patients achieve recommended blood‑pressure targets and reduces the risk of cardiovascular complications associated with hypertension.
How does olmesartan medoxomil work?+
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB). It selectively blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and stimulating aldosterone release. This results in relaxed blood vessels and reduced fluid retention, which together lower systemic blood pressure.
What is the usual dose of Olmita?+
The dose of Olmita is individualized by a prescriber based on the patient’s blood‑pressure level, response to therapy, and any co‑existing medical conditions. Healthcare professionals determine the appropriate strength and dosing schedule, which is typically taken once daily.
Is Olmita safe during pregnancy or breastfeeding?+
Olmita is contraindicated in pregnancy because the ARB component can cause fetal harm, especially in the second and third trimesters. Breastfeeding is not recommended without medical advice, as the drugs may pass into milk and affect the infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.
How do I order Olmita from GNH USA?+
To request Olmita, visit the product page on gnh-usa.com, enter the required quantity, and submit the enquiry form. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Olmita compare with other antihypertensive options?+
Olmita combines an ARB (olmesartan) with a calcium‑channel blocker (amlodipine), offering dual‑mechanism blood‑pressure control in a single tablet. Compared with monotherapy, the combination can provide greater efficacy, simplify dosing, and improve adherence. Alternatives may include ACE‑inhibitor/CCB combos or separate tablets, but the fixed‑dose format reduces pill burden.
What are the storage requirements for Olmita?+
Olmita tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme temperatures.
How is Olmita administered?+
Olmita is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water. Patients should follow the prescribing clinician’s instructions regarding timing and any specific dietary considerations.
What are the most serious risks associated with Olmita?+
The most serious risks include angio‑edema, severe hypotension, significant kidney function decline, and hyper‑kalemia. Patients should be educated to seek immediate medical attention if they experience rapid swelling of the face, lips or throat, fainting, or any signs of allergic reaction.
Who should not use Olmita?+
Olmita should not be used by individuals who are pregnant, have known hypersensitivity to olmesartan, amlodipine or any excipients, or are currently receiving another ARB, ACE inhibitor, or direct renin inhibitor. Caution is also advised for patients with severe renal or hepatic impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Olmesartan Medoxomil, Amlodipine
Route
Oral Use
Manufacturer
Krka, D.D., Novo Mesto
Origin
EU

Related products

Albis

Albis

Olmesartan Medoxomil, Amlodipine

Laboratorios Alter, S.A.
EU
Almacor Duo

Almacor Duo

Olmesartan Medoxomil, Amlodipine

Antibiotice Sa
EU
Alsamod

Alsamod

Olmesartan Medoxomil, Amlodipine

Krka, D.D., Novo Mesto
EU
Amelior

Amelior

Olmesartan Medoxomil, Amlodipine

Menarini International Operations Luxembourg S.A.
EU